Skip Navigation


European Heart Journal Advance Access originally published online on October 14, 2007
European Heart Journal 2007 28(21):2559-2560; doi:10.1093/eurheartj/ehl195
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
28/21/2559    most recent
ehl195v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Zeymer, U.
Right arrow Articles by Zahn, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zeymer, U.
Right arrow Articles by Zahn, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Drug-eluting stents: effective and safe for every patient and every lesion?

Uwe Zeymer1,* and Ralf Zahn2

1 Herzzentrum Ludwigshafen, Department of Cardiology, Medizinische Klinik B, Bremserstrasse 79, D-67063 Ludwigshafen, Germany
2 Klinikum Nürnberg-Süd, Medizinische Klinik 8, Germany

* Corresponding author. Tel: +49621 503 4045; fax: +49621 503 4002. E-mail address: uwe.zeymer@t-online.de

This editorial refers to ‘TAXUS VI 2 year follow up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions’ by E. Grube et al., on page 2578

Footnotes

The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.

The first 10% of the full text of this article appears below.

When Andreas Grüntzig performed the first percutaneous transluminal coronary angioplasty in 1978, he did not expect that this procedure would become one of the most often performed interventions in medicine worldwide. The Achilles' heels of balloon angioplasty were early reocclusions and restenosis. However, >60% of the patients after plain old balloon angioplasty did well without any need for repeat target lesion revascularizations. With the introduction of stents, the procedure became more predictable with respect to early reocclusions and the rate of clinically driven repeat revascularization procedures declined to ~20%, depending on lesion characteristics such as vessel diameter and lesion length . . . [Full Text of this Article]

Benefit of drug-eluting stents

Problems of the randomized DES trials

DES in long, complex lesions

Pending problems with DES

Future developments

Summary


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions
Eberhard Grube, Keith D. Dawkins, Giulio Guagliumi, Adrian P. Banning, Krzysztof Zmudka, Antonio Colombo, Leif Thuesen, Karl Hauptman, Jean Marco, William Wijns, Jeffrey J. Popma, Lutz Buellesfeld, Joerg Koglin, and Mary E. Russell
EHJ 2007 28: 2578-2582. [Abstract] [Full Text]